Physician profile
John Zou
NPI 1205401296
$3,067.37
in general payments reported to CMS, 2019-2025
19 companies · $912 in 2025
The $912 reported for 2025 was more than what 89% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $145 · 2022: $422 · 2023: $943 · 2024: $646 · 2025: $912.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,500.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,500.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Oyster Point Pharma, INC. | $693.25 | 2022-2025 | Tyrvaya, Ryzumvi |
| Abbvie INC. | $556.67 | 2022-2025 | Lumigan, Vuity, Alphagan P |
| Bausch & Lomb Americas INC. | $513.50 | 2023-2025 | Miebo, Xiidra, Vyzulta |
| Sun Pharmaceutical Industries INC. | $369.57 | 2021-2025 | Cequa |
| Mallinckrodt Hospital Products INC. | $305.98 | 2021-2025 | Acthar |
| New World Medical,INC. | $161.57 | 2022 | |
| Sight Sciences, INC. | $98.17 | 2025 | Omni Surgical System |
| Alcon Vision LLC | $93.09 | 2024-2025 | Rocklatan |
| Novartis Pharmaceuticals Corporation | $46.65 | 2022-2023 | |
| Dompe US, INC. | $35.91 | 2024-2025 | Oxervate |
| Aerie Pharmaceuticals, INC. | $31.57 | 2021 | |
| Astellas Pharma US INC | $25.98 | 2025 | Izervay |
| Horizon Therapeutics Plc | $24.31 | 2023 | Tepezza |
| Biotissue Holdings INC. | $23.34 | 2025 | |
| Thea Pharma INC. | $20.36 | 2023 | Iyuzeh |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Rxsight INC | $19.48 | 2025 | Rxsight Contact Lens, Rxsight Injector Cartridge, Light Adjustable Lens (Lal) |
| Harrow Eye, LLC | $19.16 | 2025 | Vevye |
| Tarsus Pharmaceuticals, INC. | $15.61 | 2025 | Xdemvy |
| Allergan, INC. | $13.20 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Zou listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.